Compare JVA & NEUP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | JVA | NEUP |
|---|---|---|
| Founded | 1971 | 1996 |
| Country | United States | United States |
| Employees | 92 | N/A |
| Industry | Packaged Foods | |
| Sector | Consumer Staples | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.4M | 18.5M |
| IPO Year | 1997 | 2002 |
| Metric | JVA | NEUP |
|---|---|---|
| Price | $4.63 | $3.32 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 76.6K | 11.6K |
| Earning Date | 09-11-2026 | 11-13-2026 |
| Dividend Yield | ★ 1.73% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.68 | N/A |
| Revenue | ★ $90,655,294.00 | $1,174,165.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $6.81 | ★ N/A |
| Revenue Growth | ★ 17.54 | N/A |
| 52 Week Low | $2.93 | $3.19 |
| 52 Week High | $5.03 | $17.90 |
| Indicator | JVA | NEUP |
|---|---|---|
| Relative Strength Index (RSI) | 67.92 | 20.00 |
| Support Level | $4.15 | $3.28 |
| Resistance Level | $4.59 | $3.86 |
| Average True Range (ATR) | 0.18 | 0.07 |
| MACD | 0.05 | -0.02 |
| Stochastic Oscillator | 79.16 | 4.60 |
Coffee Holding Co Inc is engaged in wholesale coffee operations, including manufacturing, roasting, packaging, marketing, and distributing roasted and blended coffees for privately labeled accounts and its brands, and it sells green coffee. The Company also manufactures and sells coffee roasters. Its products include wholesale green coffee, private-label coffee, and branded coffee. The company sells its coffee products throughout the United States, Canada, and certain Asian countries. The group's services are Custom Blending, Food Service Programs, and Private Label Services.
Neuphoria Therapeutics Inc is a clinical-stage biotechnology company focused on therapies for serious central nervous system disorders. Its lead product candidate, BNC210, is an oral, proprietary, selective negative allosteric modulator of the alpha7 nicotinic acetylcholine receptor. The company has discontinued development of BNC210 for social anxiety disorder, while its BNC210 program for post-traumatic stress disorder is currently paused and no active clinical trial is underway. The company operates through a single operating and reporting segment focused on the discovery and development of allosteric ion-channel modulators for serious CNS disorders with high unmet medical need.